My 1982

Li Zhongxin did not care about Li Chengfeng, and the heart began to calculate it. He went to Li Chengfeng's office, which would get some benefits from this old man!

Li Zhongxin suddenly thought that Li Chengfeng was the minister of the Ministry of Machinery. In the central ministries, he worked in agency such as the National Patent Office. He should have exposed a lot, since the loyalty and research base is said to Li Chengfeng, the machine The benefits of this are given, then, he should let Li Chengfeng bleed from bleeding, giving him the country's patent office.

In China, paten ownership, a patent certificate, awarded patent, is a national patent office, within the deadline of the national patent office, in the predetermined period of law (some countries also included importing this patent invention or design) Right (also known as monopoly or exclusive rights).

Others must agree to the above behavior through patenters, otherwise it is infringement. After the expiration of the patent period, the patent right is eliminated. Anyone can use this invention or design freely.

China! In eight four years, it is proposed, and the trial operation will be started on April 1, 85. In order to protect the legitimate rights and interests of the patent, encourage the invention, promote the application of the invention, improve innovation ability, and promote scientific and technological progress. And the development of economic and social development has developed a patent law.

The purpose of China's promulgation and implementation patent law is to promote market resources to actively invest in the direction of the increasingly increasingly increasingly increasingly increasingly increasingly producing, and promote the prosperity of economic industry.

To this end, the state gives the law proceed to the monopoly rights within a certain period of time, and it is required to disclose the content of the invention to the whole society, in order to improve the willingness of the market, promote the rapid social overall technology level Accumulation and development.

Li Zhongxin's patented technology is in international registration, because China has not yet engaged in this kind of national patent office.

Li Zhongxin clearly remembers that China has taken how many wools have been taken by patents in the next few decades in the next few decades.

Some research institutions in China have not much understanding for patent law and patent these things. They all think that in China, patented this kind of thing is too much to use.

Moreover, they think that the big money to make patented certification, it is a thing.

Make up a thing that can get patented, basically empty the home of these researchers, and they don't have those money or want to find someone to register their patents.

They have studied things, as long as they can be listed in advance, occupying the market in advance, as behind the things, even if someone imitates, they don't worry too much.

In China, the wind that brought to the people is very serious. This is also a biggest reason in China's cottage in the future.

R & D is a lot of cost, and the R & D can not make money, all unknown things.

However, if you have known things that you can make money to imitate production, what you have produced, the cost is naturally low, then they can quickly occupy the market, and I will not take this thing if I have patent rights.

It is such an idea that China has eaten a big loss on the issue of the low-end tip and patent rights, even after paying the price of blood, they will understand the importance of patents.

Li Zhongxin remembered very clearly. When later generation, the relatives in the family suffered lung cancer.

When checking out is lung cancer, it is already late in lung cancer.

This time! The relatives start targeted treatment under the discussion of the attending doctor.

The first generation of lung cancer targeted therapeutic drugs is called Yi Ruisha. This thing is a drug developed by Western developed countries. In the international market, Chinese people want to buy genuine Yi Ruisha to have a hundred million yuan, and The Indian version of Yi Richa, only one hundred dollar bills in India.

Chinese people want to eat such drugs, basically spend the most expensive money to buy, or buy them over India.

The biggest reason for this thing is that China has not aware enough for the patent law at that time, and does not buy the patent use of this drug, and China will not work like India, what patent mandatory licensing system, that is, in special circumstances Under, you can have a grant by the government without the consent of the patentee, and other companies can use a patent.

In other words, when the poor can't afford a high price, India allows the drug to be directly imitated regardless of whether the patent protection period ends.

The Indian government did this to break the monopoly of European and American pharmaceuticals, which is a life-saving medicine for the poor, but this is actually an act of ignoring the intellectual property rights of drugs. It is "I am poor, so I have reasonable, you have money, you should make me imitation "The robber logic.

Patent Protection is a criterion in the world, but also a law that will be confirmed by everyone.

Of course, other countries can certainly imitate drugs, but no India is so straightforward and stronger. However, its unsolicient rules directly benefit from the ordinary people who can't afford the high price drug.

This allows the imitation drug to fall into a two difficulties: it is of course impeccable in morality, but it is not legal.

Many people may not know how much money and manpower will be taken in a new drug, and have to fail and repeated experiments, as well as clinical test phases.

This cost is extremely huge, and the general companies are not affordable. A few major well-known drugs in the world, developing a special medicine in the United States, Switzerland, Germany, R & D costs, to reach a cost of several billions or even billions of dollars.

This kind of investment will be distributed to the drug price after the new drug is listed, so new special medicines are often very expensive because it contains R & D expenses.

Indian imitation drugs are directly bypassing the R & D stage, and it can be made into biosimilar within 3 months in the original research medicine. This kind of imitation drug may only have about 80% of the primary medicine, but the price is only 1/10 of the primary medicine.

For example, the special medicine for treating chronic granulocyte leukemia is "Greny" developed by Novarti, Switzerland, approximately 23,000 yuan, and its imitation drug Veenat is only more than 200 yuan, produced by India's drug enterprise NAT, the effectiveness of the two The ingredients are imatib, but the price is very vast.

In addition to Glerites, other special effects, such as Hecein, treating breast cancer, the treatment of lung cancer, Treating renal cell carcinoma and Duplex, India has their imitation drugs.

Li Zhongxin felt that he and Li Chengfeng need to talk about a matter of patents. If he can take the line through Li Chengfeng and the national patent office, it will be developed over the way, and enter China. The patent sequence does not have much problem. ()

Please remember the first domain name of this book:. Mobile version Read Website:

(Remember this website, .773buy. For the next reading, or Baidu entered "773Buy", you can enter this site)